Prostate Cancer - Results from #21960

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy - Abstract October 29, 2013

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer - Abstract October 28, 2013

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial - Abstract October 28, 2013

Cancer-induced bone pain: Mechanisms and models - Abstract October 28, 2013

Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer - Abstract October 28, 2013

Measuring and predicting prostate cancer related quality of life changes using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) - Abstract October 28, 2013

Innovations in diagnostic imaging of localized prostate cancer - Abstract October 28, 2013

A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland - Abstract October 28, 2013

An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the South - Abstract October 28, 2013

Exploring prostate cancer literacy and family cancer awareness in college students: Getting ahead of the curve in cancer education - Abstract October 28, 2013

Bilateral cancer in prostate biopsy associates with the presence of extracapsular disease and positive surgical margins in low risk patients: A consideration for bilateral nerve sparing radical prostatectomy decision - Abstract October 28, 2013

Two sequential diagnoses of atypical foci suspicious for carcinoma on prostate biopsy: A follow-up study of 179 cases - Abstract October 26, 2013

Recommendations from the EGAPP Working Group: Does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? - Abstract October 25, 2013

Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer - Abstract October 25, 2013

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone - Abstract October 25, 2013

Population-based study of predictors for adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer - Abstract October 25, 2013

Changing presentation of prostate cancer in a UK population - 10 Year trends in prostate cancer risk profiles in the East of England - Abstract October 25, 2013

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer - Abstract October 25, 2013

Lack of association between COX-2 staining level and biochemical recurrence following salvage radiation therapy for recurrent prostate cancer - Abstract October 25, 2013

Social epidemiology: A tool for examining prostate cancer early-detection decision making among older African American men - Abstract October 25, 2013

Page 1099 of 1436